Abstract
Standard treatment for metastatic gastric cancer (GC) is chemotherapy (CT). Most commonly, first-line chemotherapy is based on a combination of fluoropyrimidines, platinum derivates, and, in case of a HER2 overexpression, trastuzumab. First choice for second-line chemotherapy is paclitaxel associated with ramucirumab. However, there is a dearth of data about the optimal second-line treatment in patients (pts) who progress on first-line treatment including taxanes. For these pts, second-line paclitaxel and ramucirumab could incur in lack of efficacy due to taxanes cross-resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
